Mikhail Aizikovich Sherman

Mikhail Aizikovich Sherman

Auto-generated profile, based on publicly available information

Mikhail Aizikovich Sherman

Kirov State Medical University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2022 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
ABAlexey Boyko
Alexey Boyko
KBK. Z. Bakhtiyarova
K. Z. Bakhtiyarova
MSM. A. Sherman
M. A. Sherman
ZGZ. A. Goncharova
Z. A. Goncharova
ISI. V. Smagina
I. V. Smagina
ILI. S. Lozovskaya
I. S. Lozovskaya
Multiple sclerosis (MS) is a chronic autoimmune inflammatory demyelinating and neurodegenerative disease of the central nervous system. Now 2.8 million people in the world suffer from MS, since 2000 every 5 years there has been an increase in the number of MS patients by 10%. At the same time, the number of cases with highly active MS (HAMS) is increasing, i.e. cases of MS with two or more exacerbations without taking specific pathogenetic therapy or one exacerbation during taking MS disease-modifying therapies (DMTsMS), which is accompanied by the corresponding MRI data of the brain and spinal cord (presence of new or active lesions). Previously, there were no studies of quality of life (QoL) in this subgroup of patients in the world.Objective: to compare the QoL indicators of patients with HAMS with those of healthy people and patients with a typical course of relapsingremitting MS (RRMS).Patients and methods. The study included data on 518 patients from 14 regions of the Russian Federation for 2020–2021 years, in whom HAMS was confirmed during a second examination. We used the results of the analysis of clinical data from neurologists and data from questionnaires filled out by patients with HAMS. Two questionnaires were used in the work – the general (non-specific) Questionnaire for assessing the QoL, SF-36 (The MOS 36-item Short-Form Health Survey) and a special questionnaire for MS patients – MusiQoL (Multiple sclerosis Quality of Life).Results and discussion. Almost all indicators of QoL in HAMS were below the control. When compared with the typical course of RRMS, a more pronounced decrease in daily activity indicators, a significant impact of clinical symptoms on QoL, a negative attitude of patients towards the healthcare system, and a low overall health index were noted. Pearson correlation analysis revealed a stronger effect on QoL parameters of the frequency of exacerbations in HAMS than in RRMS.Conclusion. The data obtained in the study indicate the need for more active management of patients with HAMS using second-line DMTsMS.

1 January 2021 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MSM.A. Sherman
M.A. Sherman
ABA.N. Boyko
A.N. Boyko
Заболевания спектра оптиконейромиелита (ЗСОНМ) — группа редких, преимущественно тяжелых аутоиммунных демиелинизирующих заболеваний центральной нервной системы с распространенностью 0,7—10 на 100 000 человек и заболеваемостью 0,037—0,73 на 100 000 человеко-лет. Патологический симптомокомплекс представлен различными комбинациями одно- или двустороннего оптического неврита, поперечного миелита, признаков вовлечения ствола и иных отделов головного мозга, имеющими в основном (до 97,5% случаев) рецидивирующее прогрессирующее течение. Возникновение рецидивов связано с серопозитивностью к аквапорину 4 (до 80% пациентов с ЗСОНМ) и имеет менее благоприятный прогноз (летальность до 32%). Заболевание отличается поздним для демиелинизирующей патологии дебютом (средний возраст 39 лет) и высокой коморбидностью с другими аутоиммуными заболеваниями, прежде всего, системной красной волчанкой, миастенией и синдромом Шегрена, а также преобладанием (до 90%) среди серопозитивных к аквапорину-4 женщин. Отличительная особенность ЗСОНМ — этническая и генетическая предрасположенность в виде превалирования у лиц африканского и азиатского происхождения (основная ассоциация повышенного риска болезни для азиатов — HLA-DRB1*03:01). Данные факторы сопровождаются более тяжелым течением процесса (у африканцев), а также географической кластеризацией заболевания на Карибах и Дальнем Востоке. Неуклонный рост распространенности и ежегодной заболеваемости ЗСОНМ предполагает необходимость дальнейшего накопления и распространения эпидемиологических знаний с целью ранней диагностики и терапии данной прогностически неблагоприятной патологии.

21 August 2023 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
TST. O. Simaniv
T. O. Simaniv
KBK. Z. Bakhtiyarova
K. Z. Bakhtiyarova
ABAnna Belova
Anna Belova
ZGZ. A. Goncharova
Z. A. Goncharova
SSStella Sivertseva
Stella Sivertseva
ABAlexey Boyko
Alexey Boyko
Neuromyelitis optic spectrum disorders (NMOSD) are rare, severely disabling diseases of the central nervous system. They are characterized by periodic, unpredictable exacerbations that lead to an accumulation of irreversible neurologic damage. Despite existing possibilities for diagnosing NMOSD, it can be difficult to make the correct diagnosis in clinical practice. Current treatment options for NMOSD include drugs that affect the pathogenesis of the disease, including complement C5 inhibitors, with which experience is still limited, but published data from clinical trials demonstrate high efficacy of these drugs with an acceptable safety profile. The article reviews the main current approaches to the diagnosis and treatment of NMOSD.

1 January 2019 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
PDF file
HSHaggai Schermann
Haggai Schermann
IPIrina Victorovna Ponomareva
Irina Victorovna Ponomareva
VMVasily Gennadievich Maltsev
Vasily Gennadievich Maltsev
KYKonstantin Borisovich Yakushev
Konstantin Borisovich Yakushev
MSMikhail Aizikovich Sherman
Mikhail Aizikovich Sherman
The clinical picture of immunomediator disorders of the central nervous system resulting from autoimmune or paraneoplastic processes is often represented by the limbic symptom complex or limbic encephalitis. The article gives a brief description of these conditions, allocated to a separate nosological group in 2007. The symptoms of limbic encephalitis include mental disorders and epileptic seizures of both convulsive and non-convulsive spectrum, up to epileptic status. Four clinical cases representative of different variants of limbic encephalitis are presented in this study, along with the discussion of epidemiology, differential diagnostics, and generally accepted patient management strategies. The diagnosis of limbic encephalitis was made on clinical grounds alone in three cases and on the presence of antibodies to N-Methyl-d-aspartic acid receptors in one case. A combination of glucocorticoid pulse therapy with prolonged use of valproic acid was successfully applied for the treatment of limbic encephalitis with non-convulsive epileptic status. Plasmapheresis was used for the treatment of limbic encephalitis with recurrent focal non-motor attacks with and without loss of consciousness, as well as for limbic encephalitis with focal motor attacks. Presented cases emphasize the need to increase the awareness of physicians of various specialties to autoimmune disorders of the nervous system. In addition, it highlights the necessity of complete diagnostic workup for a patient with impaired consciousness of unclear etiology.

1 January 2019 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
PDF file
ABA N Boyko
A N Boyko
LBL P Bosenko
L P Bosenko
VVV V Vasilovskiy
V V Vasilovskiy
LVL I Volkova
L I Volkova
MZM N Zakharova
M N Zakharova
IOI G Obukhova
I G Obukhova
To evaluate efficacy, safety, and tolerability of the treatment with teberif/interferon β-1a, to analyze safety, tolerability and dynamics of key efficacy variables after switching from referent drug rebif to biosimilar teberif in patients with remitting multiple sclerosis (RMS). During the main period of the international multicenter randomized study patients were randomized to receive treatment with teberif for 52 weeks, or rebif for 52 weeks, or placebo for 16 weeks to evaluate efficacy and safety of treatment. After the main study period, patients were group-independently switched to take open-label teberif treatment during the next 48 weeks. The analysis of multiple evaluation parameters of the efficiency during the 1st study period (blinded) and the 2nd study period (open-label) has shown that teberif and rebif demonstrate equivalent efficacy and stable 2-year efficacy of teberif was proven. There were no significant differences between teberif and rebif for all safety, and tolerability parameters. Switching from rebif to teberif didn't influence treatment efficacy. The 2-year study results confirmed a biosimilar teberif's benign tolerability and expected safety profile to other interferons β-1a in patients with RMS.

1 January 2015 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MSM. A. Sherman
M. A. Sherman
IAI. V. Ardashev
I. V. Ardashev
A brief literature review on autoimmune inflammatory-demyelinating CNS disease - Devic's opticomyelitis, which is rare in Caucasians, is presented. We report a case of this disease. Epidemiological issues, differential diagnosis of opticomyelitis from multiple sclerosis and other non-demyelinating diseases are considered. Common strategies of patient management and perspectives of development of specific treatment of opticomyelitis are outlined.